About Cellectricon



 

Superior Cell Biology Screening Solutions


Cellectricon AB headquartered in Gothenburg, Sweden, is a leading life sciences solutions provider of advanced cell based screening products to accelerate drug discovery. The company’s products include the industry leading platforms for high resolution ion-channel screening, and cell engineering.

The Company captures the emerging paradigm shift in drug discovery towards microfluidic assays, and the products are designed to enable substantial productivity increases with maximized data quality, throughput and analytical precision. Cellectricon has a solid scientific foundation in comprehensive research results that act as the starting point for the business. Today, the company holds a solid patent portfolio in a variety of areas such as electrophysiology, microfluidics, microfabrication, and electroporation.

Cellectricon's technology platforms enable cell biology research through:

- Automated Patch Clamp Screening

- High throughput transfection

- High throughput cell processing and analysis

- Cell-based screening assays capable of addressing all drugable
- targets

The company has launched two product platforms Dynaflow® and Cellaxess® with outstanding market acceptance including 9 of the 10 largest pharmaceutical companies, and highly esteemed research facilities. These two platforms address the rapidly growing areas of ion channel screening, and RNAi screening. The company also has a highly promising product pipeline addressing several high growth markets within cell biology. Future areas include broad cell assay coverage for drug screening and clinical areas such as Cloning, IVF & Gene manipulation.

Owners
Cellectricon is a privately held company. The main shareholders are Ägir Invest, Dunross & Co, Investor Growth Capital and Innovations Kapital, together with employees and seed investors.

Founders

Cellectricon was founded in late 2000 based on ten years of internationally renowned research and an extensive and solid patent portfolio by:

Dr. Daniel T. Chiu, Assistant Professor of Chemistry at the University of Washington, Seattle.

Jakob Lindberg, Former CEO at Cellectricon (2000-2004). Prior to his position at Cellectricon AB, Jakob Lindberg worked as a consultant at McKinsey & Co.

Dr. Owe Orwar, Professor at the Department of Physical Chemistry at Chalmers University of Technology, Gothenburg.